Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury

Justin M. Belcher, Arun J. Sanyal, Aldo J. Peixoto, Mark A. Perazella, Joseph Lim, Heather Thiessen-Philbrook, Naheed Ansari, Steven G. Coca, Guadalupe Garcia-Tsao, Chirag R. Parikh

Research output: Contribution to journalArticle

Abstract

Acute kidney injury (AKI) is common in patients with cirrhosis and associated with significant mortality. The most common etiologies of AKI in this setting are prerenal azotemia (PRA), acute tubular necrosis (ATN), and hepatorenal syndrome (HRS). Accurately distinguishing the etiology of AKI is critical, as treatments differ markedly. However, establishing an accurate differential diagnosis is extremely challenging. Urinary biomarkers of kidney injury distinguish structural from functional causes of AKI and may facilitate more accurate and rapid diagnoses. We conducted a multicenter, prospective cohort study of patients with cirrhosis and AKI assessing multiple biomarkers for differential diagnosis of clinically adjudicated AKI. Patients (n=36) whose creatinine returned to within 25% of their baseline within 48 hours were diagnosed with PRA. In addition, 76 patients with progressive AKI were diagnosed by way of blinded retrospective adjudication. Of these progressors, 39 (53%) patients were diagnosed with ATN, 19 (26%) with PRA, and 16 (22%) with HRS. Median values for neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), and albumin differed between etiologies and were significantly higher in patients adjudicated with ATN. The fractional excretion of sodium (FENa) was lowest in patients with HRS, 0.10%, but did not differ between those with PRA, 0.27%, or ATN, 0.31%, P=0.54. The likelihood of being diagnosed with ATN increased step-wise with the number of biomarkers above optimal diagnostic cutoffs. Conclusion: Urinary biomarkers of kidney injury are elevated in patients with cirrhosis and AKI due to ATN. Incorporating biomarkers into clinical decision making has the potential to more accurately guide treatment by establishing which patients have structural injury underlying their AKI. Further research is required to document biomarkers specific to HRS. (Hepatology 2014;60:622-632)

Original languageEnglish (US)
Pages (from-to)622-632
Number of pages11
JournalHepatology
Volume60
Issue number2
DOIs
StatePublished - Aug 2014

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury'. Together they form a unique fingerprint.

  • Cite this

    Belcher, J. M., Sanyal, A. J., Peixoto, A. J., Perazella, M. A., Lim, J., Thiessen-Philbrook, H., Ansari, N., Coca, S. G., Garcia-Tsao, G., & Parikh, C. R. (2014). Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology, 60(2), 622-632. https://doi.org/10.1002/hep.26980